- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05819164
Comparison of Multiple Oxygenation Targets With Different Oximeters in Chronic Obstructive Pulmonary Disease (COPD) and Non-COPD Patients- Impact on Oxygen Flows
Comparison of Multiple Oxygenation Targets With Different Oximeters in COPD and Non-COPD Patients- Impact on Oxygen Flows
The oximeter is an instrument for monitoring patients receiving oxygen therapy. It displays pulse oxygen saturation (SpO2), which is a reflection of arterial oxygen saturation (SaO2). An accurate SpO2 value is essential for optimal management of the O2 flow delivered to patients. Several factors can influence this measurement and the choice of ventilatory support: the type of oximeter used, skin pigmentation and the oxygenation goal.
The objective of our study is to evaluate the impact of the oxygenation goal and the oximeter used on oxygen flows in patients with COPD (or with hypercapnia, or at risk of hypercapnia) and in patients without COPD (in particular pneumonia, pulmonary fibrosis and other pathologies) Our hypothesis is that the SpO2 target and oximeter used will have an impact on oxygen flows and that these effects will be synergistic in these different populations.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Québec, Quebec, Canada, G1V4G5
- Institut universitaire de Cardiologie et de Pneumologie de Quebec
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥ 18 years old
- On conventional oxygen therapy with SpO2 between 88 and 100% with the usual oximeter and nasal cannula.
- SpO2 < 92% in ambient air with the usual oximeter
Exclusion Criteria:
- No availability of the SpO2 signal with the usual oximeter
- False nails or nail polish
- Severe anemia documented on the last blood count during the current hospitalization (Hb < 80g/L)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 88% SpO2 target
During this periods , oxygen will be administered in manual titration to reach 88% of SpO2.
|
During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
During this period, the Nellcor oximeter N-600 was used for SpO2 reading
During this period, the Nonin oximeter was used for SpO2 reading
|
|
Experimental: 90% SpO2 target
During this periods , oxygen will be administered in manual titration to reach 90% of SpO2.
|
During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
During this period, the Nellcor oximeter N-600 was used for SpO2 reading
During this period, the Nonin oximeter was used for SpO2 reading
|
|
Experimental: 92% SpO2 target
During this periods , oxygen will be administered in manual titration to reach 92% of SpO2.
|
During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
During this period, the Nellcor oximeter N-600 was used for SpO2 reading
During this period, the Nonin oximeter was used for SpO2 reading
|
|
Experimental: 94% SpO2 target
During this periods , oxygen will be administered in manual titration to reach 94% of SpO2.
|
During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
During this period, the Nellcor oximeter N-600 was used for SpO2 reading
During this period, the Nonin oximeter was used for SpO2 reading
|
|
Experimental: 96% SpO2 target
During this periods , oxygen will be administered in manual titration to reach 96% of SpO2.
|
During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
During this period, the Nellcor oximeter N-600 was used for SpO2 reading
During this period, the Nonin oximeter was used for SpO2 reading
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxygen flow
Time Frame: assessed up to 10 minutes
|
the mean oxygen flow to reach the SpO2 target +/- 1% during 2 minutes for each period and each oximeter
|
assessed up to 10 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Partial oxygen weaning
Time Frame: assessed up to 10 minutes - until SpO2 target stability for 2 minutes
|
Rate of partial oxygen weaning (Oxygen flow <=0.5 L/min) to reach the SpO2 target for each period and each oximeter
|
assessed up to 10 minutes - until SpO2 target stability for 2 minutes
|
|
Complete oxygen weaning
Time Frame: assessed up to 10 minutes - until SpO2 target stability for 2 minutes
|
Rate of complete oxygen weaning (Oxygen flow <=0.1 L/min) to reach the SpO2 target for each period and each oximeter
|
assessed up to 10 minutes - until SpO2 target stability for 2 minutes
|
|
High oxygen flow
Time Frame: assessed up to 10 minutes - until SpO2 target stability for 2 minutes
|
Rate of high oxygen flow (Oxygen flow >5.0 L/min) to reach the SpO2 target for each period and each oximeter
|
assessed up to 10 minutes - until SpO2 target stability for 2 minutes
|
|
Oximeter bias comparison
Time Frame: assessed up to 10 minutes - until SpO2 target stability for 2 minutes
|
the mean bias between the result of the different oximeter
|
assessed up to 10 minutes - until SpO2 target stability for 2 minutes
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-4002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.